[Phase I, II studies of recombinant granulocyte colony stimulating factor (gamma hG-CSF)].
Results obtained in phase I-II studies of gamma hG-CSF were reviewed. An optimal dose of Japanese patients with malignant diseases was judged to be 100-200 micrograms/m2 by 30 minutes infusion and 75 micrograms per body by subcutaneous injection. Neutrophils were increased dose-related while other blood components did not increase. When gamma hG-CSF was used following chemotherapy, it enhanced the nadirs of leukopenia and reduced significantly durations of neutropenic periods. Bone pain was characteristic side effect and occurred dose-dependently but generally mild.
Ogawa
M
M
Cancer Chemotherapy Center, Japanese Foundation for Cancer Research.
D003115:Colony-Stimulating Factors / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D004341:Drug Evaluation; D016179:Granulocyte Colony-Stimulating Factor; D006801:Humans; D007958:Leukocyte Count; D007970:Leukopenia / Q000097:blood / Q000628:therapy; D008297:Male; D009369:Neoplasms / Q000097:blood / Q000628:therapy*; D009504:Neutrophils; D011994:Recombinant Proteins / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use
D003115:Colony-Stimulating Factors; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor